Recently, interim analyses to evaluate the efficacy and safety of anti-PD-1/PD-L1 monotherapy for metastatic breast cancer have been carried out; 586 advanced breast cancer patients treated with anti-PD-1/PD-L1 monotherapy agents were included from six studies. Here, CD274 is linked to breast carcinoma.